

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
July 14, 2020

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Yvette Waples, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Massimo Cristofanilli, MD, FACP

Associate Director of Translational Research and
Precision Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Jorge A. Garcia, MD, FACP

Chair, Division of Solid Tumor Oncology
George and Edith Richman Distinguished Scientist
Chair
Director, GU Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Christian S. Hinrichs, MD

Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology
Branch
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Bethesda, Maryland

Philip Hoffman, MD

(Chairperson)
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

David Mitchell

(Consumer Representative)
Founder, Patients for Affordable Drugs
Bethesda, Maryland

Anthony D. Sung, MD

Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
July 14, 2020

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)

Vice President and Oncology Therapeutic Area
Head, Merck Research Laboratories, Oncology
Clinical Research
North Wales, Pennsylvania

TEMPORARY MEMBERS (Voting)

James Chodosh, MD, MPH

Edith Ives Cogan Professor of Ophthalmology
Massachusetts Eye and Ear
Harvard Medical School
Boston, Massachusetts

John DeFlice, MD

(Patient Representative)
Albuquerque, New Mexico

Brad H. Feldman, MD

Assistant Professor of Ophthalmology
Wills Eye Hospital and Thomas Jefferson University
Philadelphia, Pennsylvania

Heidi D. Klepin, MD, MS

Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Grzegorz S. Nowakowski, MD

Assistant Professor of Medicine
Mayo Clinic Rochester
Rochester, Minnesota

Gita Thanarajasingam, MD

Consultant, Division of Hematology
Assistant Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Thomas S. Uldrick, MD, MS

Deputy Head, Global Oncology
Associate Member, Vaccine and Infectious Disease
and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine
University of Washington
Seattle, Washington

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
July 14, 2020

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Acting Director, Office of Oncologic Disease (OOD)
Office of New Drugs (OND), CDER, FDA

Nicole Gormley, MD

Director (Acting)
Division of Hematologic Malignancies 2 (DHM2)
OOD, OND, CDER, FDA

Bindu Kanapuru, MD

Multiple Myeloma Team Lead (Acting)
DHM2, OOD, OND, CDER, FDA

Andrea Baines, MD, PhD

Clinical Reviewer
DHM2, OOD, OND, CDER, FDA

Wiley Chambers, MD

Director (Acting)
Division of Ophthalmology
Office of Specialty Medicine
OND, CDER, FDA